This page catalogs biotechnology and pharmaceutical companies developing myelin repair, oligodendrocyte protection, and remyelination therapies for Alzheimer's disease. While traditionally associated with multiple sclerosis, oligodendrocyte dysfunction and white matter pathology are increasingly recognized as significant contributors to AD progression.
White matter abnormalities are a prominent feature of AD pathophysiology. Post-mortem studies demonstrate widespread white matter damage, including[@chen2018]:
In tauopathies including AD, oligodendrocytes contain tau-positive inclusion bodies, contributing to myelin dysfunction beyond the classical neuronal pathology[@Ferrer2014].
| Approach | Description | Companies |
|---|---|---|
| Oligodendrocyte Protection | Protecting oligodendrocytes from tau pathology and oxidative stress | Clene, Retrotope |
| OPC Activation | Activating oligodendrocyte precursor cells for remyelination | Sanofi, Biogen |
| Remyelination Enhancement | Enhancing the remyelination process | Clene, Vaccinex |
| Myelin Stabilization | Stabilizing existing myelin sheaths | Multiple approaches |
Status: Phase 2 (ALS, PD, MS); Preclinical (AD)
Clene Nanomedicine is a clinical-stage biopharmaceutical company developing CNM-Au8®, a gold nanocrystal suspension designed to target cellular energy impairment in neurodegenerative diseases. While primarily focused on ALS and MS, Clene's remyelination approach has relevance for AD:
| Attribute | Details |
|---|---|
| Lead Candidate | CNM-Au8® |
| Mechanism | Clean-surface nanocrystals (CSN™) targeting cellular bioenergetics |
| AD Relevance | Oligodendrocyte energy support, remyelination potential |
| Stage | Phase 2 (ALS/PD/MS), Preclinical (AD) |
Scientific Rationale: CNM-Au8® has demonstrated enhancement of remyelination in preclinical cuprizone models of MS. The mechanism involves supporting oligodendrocyte function and myelin integrity[@mei2014], which may translate to AD where oligodendrocyte dysfunction contributes to white matter pathology.
Status: Preclinical (AD program)
Vaccinex is developing anti-LINGO-1 antibodies as a remyelination therapy:
| Attribute | Details |
|---|---|
| Focus | LINGO-1 inhibition |
| Mechanism | Anti-LINGO-1 monoclonal antibody blocks negative regulator of OPC differentiation |
| AD Relevance | OPC activation for myelin repair |
| Stage | Preclinical |
Scientific Rationale: LINGO-1 is a negative regulator of oligodendrocyte precursor cell (OPC) differentiation. Inhibiting LINGO-1 promotes OPC maturation into oligodendrocytes and enhances remyelination. While primarily developed for MS, the same mechanism could potentially address white matter pathology in AD.
Status: Discovery/Preclinical
Retrotope is developing therapies targeting lipid peroxidation and mitochondrial dysfunction:
| Attribute | Details |
|---|---|
| Focus | D-PUFA (deuterated polyunsaturated fatty acids) |
| Mechanism | Prevents lipid peroxidation, protects mitochondrial function |
| AD Relevance | Oligodendrocyte protection from oxidative damage |
| Stage | Discovery |
Scientific Rationale: Oligodendrocytes are particularly vulnerable to oxidative stress due to their high iron content and lipid-rich myelin. Retrotope's D-PUFA approach protects against lipid peroxidation, potentially preserving oligodendrocyte function in AD.
Status: Clinical (MS); Preclinical exploration (AD)
Biogen has developed opicinumab (anti-LINGO-1 antibody) for MS:
| Attribute | Details |
|---|---|
| Lead Candidate | Opicinumab (BG00012) |
| Mechanism | Anti-LINGO-1 monoclonal antibody |
| AD Relevance | OPC activation, remyelination enhancement |
| Stage | Phase 2 (MS); exploring AD |
Notes: Biogen's anti-LINGO-1 program demonstrated promise in MS for promoting remyelination. The company is exploring whether similar approaches could benefit AD patients with white matter pathology.
Status: Research/Preclinical
Sanofi has research programs targeting oligodendrocyte biology and remyelination:
| Attribute | Details |
|---|---|
| Focus | OPC modulation, small molecule approaches |
| Mechanism | Multiple pathways including kinase inhibitors |
| AD Relevance | Direct oligodendrocyte replacement/regeneration |
| Stage | Research |
The following companies from adjacent therapeutic areas may have programs applicable to myelin/oligodendrocyte therapy in AD:
| Company | Related Program | Relevance |
|---|---|---|
| SanBio | SB623 (MSCs) | Neurotrophic support, potential oligodendrocyte protection |
| Neuralstem | Neural stem cell therapy | May include oligodendrocyte lineage cells |
| Aspen Neuroscience | iPSC-derived cells | Autologous cell therapy platform |
| BlueRock Therapeutics | Cell therapy | hESC-derived neural cells |
| Cynata Therapeutics | Cymerus™ iPSC-MSCs | Immunomodulation, potential myelin protection |
Oligodendrocytes are affected in AD through multiple mechanisms:
Addressing oligodendrocyte dysfunction in AD offers several therapeutic opportunities:
| Company | Candidate | Mechanism | Stage | AD Focus |
|---|---|---|---|---|
| Clene | CNM-Au8® | Nanocrystals, energy metabolism | Phase 2 (other), Preclinical | Exploratory |
| Vaccinex | Anti-LINGO-1 | OPC activation | Preclinical | Exploratory |
| Retrotope | D-PUFA | Lipid protection | Discovery | Exploratory |
| Biogen | Opicinumab | LINGO-1 inhibition | Phase 2 (MS) | Research |
| Sanofi | Multiple | OPC modulation | Research | Research |